Voltar
Artigo Acesso aberto Produção Nacional Revisado por pares
BIBTEX RIS

Oral Rivaroxaban for the Treatment of Symptomatic Venous Thromboembolism in 400 Patients With Active Cancer: A Single-Center Experience

2016; SAGE Publishing; Volume: 23; Issue: 7 Linguagem: Inglês

10.1177/1076029616677800

ISSN

1938-2723

Autores

Bruno Soriano Pignataro, Kenji Nishinari, Rafael Noronha Cavalcante, Guilherme Centofanti, Guilherme Yazbek, Mariana Krutman, Guilherme Andre Zotelle Bomfim, Igor Yoshio Imagawa Fonseca, Marcelo Passos Teivelis, Nelson Wolosker, Solange Moraes Sanches, Eduardo Ramacciotti,

Tópico(s)

Atrial Fibrillation Management and Outcomes

Resumo

To study the safety and efficacy of rivaroxaban-a direct oral anticoagulant-use in patients with active cancer and venous thromboembolism (VTE).Retrospective cohort study of 400 patients with active cancer and associated VTE, defined as deep venous thrombosis and/or pulmonary embolism. This single-center study was carried out from January 2012 to June 2015. The aim of this study was to determine the efficacy and safety, using the incidence of recurrent symptomatic VTE and major bleeding, respectively, throughout the treatment with rivaroxaban.Of the 400 patients enrolled, 223 (55.8%) were female. A total of 362 (90.5%) patients had solid tumors and 244 (61%) had metastatic disease. A total of 302 (75.5%) received initial parenteral therapy with enoxaparin (median: 3, mean: 5.6, standard deviation [SD]: 6.4 days) followed by rivaroxaban. Ninety-eight patients (24.5%) were treated with on label rivaroxaban treatment. Recurrence rates were 3.25% with major bleeding occurring in 5.5% during the anticoagulant therapy (median: 118, mean: 163.9, SD: 159.9 days).Rivaroxaban can be an attractive alternative for the treatment of cancer-associated thrombosis.

Referência(s)